Previous close | 67.11 |
Open | 67.87 |
Bid | 66.45 x 200 |
Ask | 66.96 x 100 |
Day's range | 66.65 - 67.87 |
52-week range | 37.87 - 70.81 |
Volume | |
Avg. volume | 145,387 |
Market cap | 1.398B |
Beta (5Y monthly) | 0.80 |
PE ratio (TTM) | 78.41 |
EPS (TTM) | 0.85 |
Earnings date | 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 79.80 |
Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New York City as follows: Capital One 1st Annual Biotech/Biopharma Disruptors Event Date:Tuesday, May 14, 2024 Time:12:15pm ET To schedule a 1x1 meeting with management, please contact kristen.patrick@capitalone.com H.C. Wa